                </a></li></ul></div><p><strong>Figure 6.  <span>Mexiletine and Ranolaziine, but not Flecainde, correct mutation-induced voltage shift in steady state inactivation.</span></strong></p><a id="article1.body1.sec2.sec4.fig2.caption1.p1" name="article1.body1.sec2.sec4.fig2.caption1.p1"></a><p>Steady state inactivation was measured with a 5s conditioning pulse (see <a href="#pone.0001258.s001">Methods S1</a>) followed by a brief −10 mV test pulse. A. Flecainide (n = 4) did not significantly alter V<sub>1/2</sub> or slope factor of the channel availability curve. B–C. Mexiletine (n = 5) and Ranolazine (n = 9) each caused significant hyperpolarizing shifts in the voltage-dependence of steady-state inactivation (<a href="#pone-0001258-t001">Table 1</a>).</p>
